RS49532B - Inkluzioni kompleksi aril-heterocikličnih soli - Google Patents

Inkluzioni kompleksi aril-heterocikličnih soli

Info

Publication number
RS49532B
RS49532B YU17297A YU17297A RS49532B RS 49532 B RS49532 B RS 49532B YU 17297 A YU17297 A YU 17297A YU 17297 A YU17297 A YU 17297A RS 49532 B RS49532 B RS 49532B
Authority
RS
Serbia
Prior art keywords
optionally substituted
phenyl
incclusion
complexs
aryl
Prior art date
Application number
YU17297A
Other languages
English (en)
Inventor
Kevin Charles Johnson
Yesook Kim
Ravi Mysore Shanker
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU17297A publication Critical patent/YU17297A/sh
Publication of RS49532B publication Critical patent/RS49532B/sr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Kompozicija supstanci, naznačena time, što obuhvata farmaceutski prihvatljivu so jedinjenja formule (I) i ciklodekstrin, u kojoj je Ar benzoizotiazolil ili njegov oksid ili dioksid svaki opciono supstituisan jednim fluorom, hlorom, trifluorometil, metoksi, cijano ili nitro grupom; n je 1 ili 2; i X i Y zajedno sa fenil ostatkom za koji su vezani obrazuju benzotiazolil, 2-aminobenzotiazolil, benzoizotiazolil, indazolil, 3-hidroksiindazolil, indolil, oksindolil opciono supstituisani sa jednim do tri (C1-C3) alkil ili jednim hlorom, fluorom ili fenil ostatkom, navedeni fenil opciono supstituisan jednim hlorom ili fluorom, benzoksazolil, 2-aminobenzoksazolil, benzoksazolonil, 2-aminobenzooksazolonil, benzotiazolonil, benzoimidazolonil ili benzotriazolil. Prijava sadrži još 1 nezavisan patentni zahtev i 22 zavisna patentna zahteva.
YU17297A 1996-05-07 1997-05-06 Inkluzioni kompleksi aril-heterocikličnih soli RS49532B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
YU17297A YU17297A (sh) 1999-12-27
RS49532B true RS49532B (sr) 2006-12-15

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
YU17297A RS49532B (sr) 1996-05-07 1997-05-06 Inkluzioni kompleksi aril-heterocikličnih soli

Country Status (47)

Country Link
US (2) US6232304B1 (sr)
EP (1) EP0900088B1 (sr)
JP (1) JP3579060B2 (sr)
KR (1) KR20000010823A (sr)
CN (1) CN1216923A (sr)
AP (1) AP796A (sr)
AR (2) AR007002A1 (sr)
AT (1) ATE257714T1 (sr)
AU (1) AU713711B2 (sr)
BG (3) BG64474B1 (sr)
BR (1) BR9709213A (sr)
CA (1) CA2251912C (sr)
CO (1) CO4600677A1 (sr)
CZ (1) CZ297847B6 (sr)
DE (1) DE69727218T2 (sr)
DK (1) DK0900088T3 (sr)
DZ (1) DZ2220A1 (sr)
EA (1) EA001731B1 (sr)
EG (1) EG24135A (sr)
ES (1) ES2212809T3 (sr)
GE (1) GEP20074185B (sr)
GT (1) GT199700044A (sr)
HN (1) HN1997000039A (sr)
HR (1) HRP970237B1 (sr)
HU (1) HU222451B1 (sr)
ID (1) ID16866A (sr)
IL (1) IL126546A (sr)
IS (1) IS2524B (sr)
MA (1) MA24172A1 (sr)
ME (1) ME00880B (sr)
MY (1) MY121999A (sr)
NO (1) NO324373B1 (sr)
NZ (1) NZ332220A (sr)
OA (1) OA10907A (sr)
PL (1) PL189324B1 (sr)
PT (1) PT900088E (sr)
RS (1) RS49532B (sr)
SA (1) SA97180024B1 (sr)
SI (1) SI0900088T1 (sr)
SK (1) SK282032B6 (sr)
TN (1) TNSN97075A1 (sr)
TR (1) TR199802231T2 (sr)
TW (1) TW514529B (sr)
UA (1) UA57734C2 (sr)
UY (1) UY24544A1 (sr)
WO (1) WO1997041896A2 (sr)
ZA (1) ZA973874B (sr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
DK0811386T3 (da) * 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
MXPA05002007A (es) * 2002-09-17 2005-04-28 Warner Lambert Co Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia.
WO2004037224A1 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
WO2004037289A2 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Novel injectable depot formulations
EP1556087A2 (en) * 2002-10-31 2005-07-27 Pfizer Products Inc. Liquid conjugates of solid pharmaceuticals
AU2003272011A1 (en) * 2002-10-31 2004-05-25 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
EP1418492B1 (en) * 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
CN1889943A (zh) * 2003-12-08 2007-01-03 美国亚利桑那大学董事会 协同抗癌组合物
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
WO2005107719A2 (en) 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20090045233A (ko) 2006-07-10 2009-05-07 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
DK0811386T3 (da) 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
PL188164B1 (pl) 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
DE69727218T2 (de) 2004-11-18
AR045528A2 (es) 2005-11-02
UY24544A1 (es) 2000-09-29
TR199802231T2 (xx) 1999-02-22
NZ332220A (en) 2000-03-27
SK282032B6 (sk) 2001-10-08
HUP9902799A2 (hu) 1999-12-28
IL126546A0 (en) 1999-08-17
NO324373B1 (no) 2007-10-01
EP0900088B1 (en) 2004-01-14
CZ346198A3 (cs) 1999-09-15
US6232304B1 (en) 2001-05-15
IL126546A (en) 2001-01-28
CZ297847B6 (cs) 2007-04-11
JP3579060B2 (ja) 2004-10-20
BG64475B1 (bg) 2005-04-30
PL189324B1 (pl) 2005-07-29
SK150498A3 (en) 2000-01-18
BR9709213A (pt) 1999-08-10
MA24172A1 (fr) 1997-12-31
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
CA2251912A1 (en) 1997-11-13
ZA973874B (en) 1998-11-06
US20010031756A1 (en) 2001-10-18
HU222451B1 (hu) 2003-07-28
CA2251912C (en) 2003-06-03
EP0900088A2 (en) 1999-03-10
AU713711B2 (en) 1999-12-09
HRP970237B1 (en) 2002-04-30
UA57734C2 (uk) 2003-07-15
AR007002A1 (es) 1999-10-13
ATE257714T1 (de) 2004-01-15
ID16866A (id) 1997-11-20
CO4600677A1 (es) 1998-05-08
IS2524B (is) 2009-07-15
EA199800910A1 (ru) 1999-04-29
AU1937297A (en) 1997-11-26
GT199700044A (es) 1998-10-02
DK0900088T3 (da) 2004-04-19
HN1997000039A (es) 1997-06-26
NO985192L (no) 1998-11-06
KR20000010823A (ko) 2000-02-25
US6399777B2 (en) 2002-06-04
JPH11509866A (ja) 1999-08-31
ES2212809T3 (es) 2004-08-01
MY121999A (en) 2006-03-31
YU17297A (sh) 1999-12-27
BG102894A (en) 1999-09-30
BG64474B1 (bg) 2005-04-30
WO1997041896A3 (en) 1998-01-08
TW514529B (en) 2002-12-21
PL329928A1 (en) 1999-04-26
TNSN97075A1 (fr) 2005-03-15
IS4880A (is) 1998-10-27
HUP9902799A3 (en) 2000-12-28
PT900088E (pt) 2004-04-30
EA001731B1 (ru) 2001-08-27
BG64475B2 (bg) 2005-04-30
ME00880B (me) 2006-12-15
AP9700977A0 (en) 1997-07-31
DZ2220A1 (fr) 2002-12-03
GEP20074185B (en) 2007-08-10
SA97180024B1 (ar) 2005-12-24
DE69727218D1 (de) 2004-02-19
WO1997041896A2 (en) 1997-11-13
HRP970237A2 (en) 1998-12-31
SI0900088T1 (en) 2004-04-30
NO985192D0 (no) 1998-11-06
OA10907A (en) 2001-10-26
AP796A (en) 1999-12-24

Similar Documents

Publication Publication Date Title
RS49532B (sr) Inkluzioni kompleksi aril-heterocikličnih soli
AR015768A1 (es) DERIVADOS DE IMIDAZO PIRIDINA QUE INHIBEN LA SECRECIoN DE ÁCIDO GÁSTRICO, COMPOSICIoN FARMACÉUTICA, PROCEDIMIENTOS PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA, USO DE DICHOS DERIVADOS PARA PREPARAR MEDICAMENTOS Y COMPUESTOS INTERMEDIARIOS uTILES EN EL PROCEDIMIENTO PARA LA PREPARACIoN DE DICHOS DE
BR9812010A (pt) Determinados ácidos 5-alquil-2-arilaminofenilacéticos e derivados
HUP0300268A2 (hu) Herbicid hatású benzoilpirazolszármazékok, ilyeneket tartalmazó készítmények és alkalmazásuk
HUP0203438A2 (hu) Foszfodiészteráz gátló hatású 5-(2-helyettesített-5-heterociklilszulfonilpirid-3-il)-dihidropirazolo[4,3-d]-pirimidin-7-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
DK1163212T3 (da) Amidderivater
HUP0003731A2 (hu) 4-Bróm- vagy 4-jód-fenil-amino-benzhidroxámsav-származékok és ilyen vegyületek MEK gátlóként való alkalmazása
RS54258B1 (sr) Formulacije inhibitora src/abl
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
HUP0102277A2 (hu) 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0001865A2 (hu) Amino-pirimidin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
PT80507A (de) Neue substituierte bis-(4-aminophenyl)-sulfone ihre herstellungund ihre verwendung als arzneimittel
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
HRP20040230B1 (en) Muscarinic agonists
TR200400237T4 (tr) Yeni karışımlar.
HUP0101469A2 (hu) 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként
DE69928646D1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen
HUP0303204A2 (hu) 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0001010A2 (hu) Benzimidazol-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP0004590A2 (hu) Endotelin-antagonista imidazolszármazékokat és béta receptor blokkolókat tartalmazó kombinációs gyógyszerkészítmények
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof